Condition: Hip or Knee Replacement · Sponsor: Clarent Biopharma, Inc.
Randomized, double-blind, clinical study to evaluate the safety and efficacy of CBP-0276 at doses of 600 mg/day in reducing opioid use in pain management in adult patients undergoing major orthopedic surgery. Subjects will be allocated in 2 groups. One group will receive oxycodone (standard of care) + CBP-0276 at a dose of 600 mg, orally once daily for 28 days. A second group will receive oxycodone (standard of care) + placebo for CBP-0276, orally once daily for 28 days
This description comes directly from the study's public registry record.
Pedro Gutiérrez Castrellón, MD, PhD · +525554198746 · pedro.gutierrez@elemental.org.mx
Diana M Andrade Platas, MD · +525535209755 · diana.andrade@elemental.org.mx
Always discuss trial participation with your own doctor first.
| Innovacion y Desarrollo de Estrategias en Salud | Mexico City, Mexico | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07687966